1-2 of 2
Vernon K. Sondak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine V. Cohen, Elizabeth I. Buchbinder, Kari Kendra, Pauline Funchain, Karl D. Lewis, Robert M. Conry, Bartosz Chmielowski, Ragini R. Kudchadkar, Douglas B. Johnson, Hongli Li, James Moon, Zeynep Eroglu, Brian Gastman, Magdalena Kovacsovics-Bankowski, Krishna S. Gunturu, Scot W. Ebbinghaus, Sama Ahsan, Nageatte Ibrahim, Elad Sharon, Larissa A. Korde, John M. Kirkwood, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2022) 12 (3): 644–653.
https://doi.org/10.1158/2159-8290.CD-21-1141
Published: 08 March 2022
View article titled, Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Open the PDF for Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma in another window
Includes: Supplementary data
Journal Articles

Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype

Kim H.T. Paraiso, Meghna Das Thakur, Bin Fang, John M. Koomen, Inna V. Fedorenko, Jobin K. John, Hensin Tsao, Keith T. Flaherty, Vernon K. Sondak, Jane L. Messina, Elena B. Pasquale, Alejandro Villagra, Uma N. Rao, John M. Kirkwood, Friedegund Meier, Sarah Sloot, Geoffrey T. Gibney, Darrin Stuart, Hussein Tawbi, Keiran S.M. Smalley
Journal: Cancer Discovery
Cancer Discov (2015) 5 (3): 264–273.
https://doi.org/10.1158/2159-8290.CD-14-0293
Published: 05 March 2015
View article titled, Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
Open the PDF for Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype in another window
Includes: Supplementary data